FDA pediatric research list
This article was originally published in The Tan Sheet
Executive Summary
Nicorette/Nicoderm CQ marketer SmithKline Beecham suggests agency request for more information on OTC nicotine in the adolescent population be expanded to 12- to 17-year-olds from FDA's proposed collection in 12- to 16-year-olds; current OTC nicotine replacement product labeling restricts usage of nicotine products to persons 18 and older. In March, FDA issued a list of drugs for which it seeks additional information on pediatric usage as required by the FDA Modernization Act. The list includes 22 other OTCs in addition to nicotine ("The Tan Sheet" March 30, p. 15). Additional pediatric information provided by companies at FDA's request could lead to six months of additional marketing exclusivity...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning